Abstract: The present disclosure provides a preparation method of a medicinal oil for reducing a gastrointestinal reaction caused by sulforaphane (SFA) and sulforaphene. In the present disclosure, the medicinal oil includes the SFA and the sulforaphene that serve as active ingredients, and the SFA and the sulforaphene each have a weight percentage content of 0.1% to 50%. An auxiliary material vegetable oil for preparing the medicinal oil is one or a mixture of two or more selected from the group consisting of soybean oil, corn oil, peanut oil, sesame oil, cottonseed oil, linseed oil, castor oil, rapeseed oil, sunflower seed oil, camellia seed oil, and olive oil. The SFA, the sulforaphene, and the auxiliary material are mixed to prepare a capsule. The medicinal oil can be used to reduce the gastrointestinal reaction caused by the SFA and the sulforaphene.

Abstract: The present disclosure provides a drug for treating prostatitis or benign prostatic hyperplasia (BPH), including sulforaphane (SFA) or an SFA-containing plant extract. In the present disclosure, the SFA, as an active ingredient, is isolated from a plant of Brassica. The plant of Brassica includes, but is not limited to, Raphanus sativus L., Brassica oleracea L. var. italica Plenck, Brassica oleracea, and Brassica juncea (L.) Czern.

Abstract: The present disclosure relates to a pharmaceutical composition for improving and treating leukotrichia and/or alopecia and a preparation method thereof. In the present disclosure, the pharmaceutical composition includes glucoraphanin and myrosinase as active ingredients, where the glucoraphanin has a content of 0.1% to 50% and the myrosinase has a total enzyme activity of 0.1 mU to 10 U based on a total weight of the pharmaceutical composition. The pharmaceutical composition shows safety, rapidity, effective improvement and treatment of leukotrichia and/or alopecia, and wide application range for subjects.

Abstract: The present disclosure provides use of sulforaphene in preparation of a pharmaceutical composition for improving and treating leukotrichia and/or alopecia, and a preparation method of the pharmaceutical composition. The sulforaphene serves as an active ingredient of the pharmaceutical composition, and the sulforaphene has a content of 0.1% to 50% based on a total weight of the pharmaceutical composition.

Abstract: The present disclosure provides a method for treating or relieving anxiety disorder by administering an effective amount of an asparagus powder, with active ingredients in the asparagus powder including: 15.0% or more of an asparagus saponin, 8% or more of a polysaccharide, 3.0% or more of a polyphenol, and 2.0% or more of a flavone.

Abstract: A method of treating or preventing human or mammalian cancer and tumor including administering to a patient or an animal in need thereof a pharmaceutical composition, a health product, or a food additive, including 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene.

Abstract: A method of treating or preventing human or mammalian cancer and tumor including administering to a patient or an animal in need thereof a pharmaceutical composition, a health product, or a food additive, including 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene.

Abstract: A method of treating or preventing human or mammalian cancer and tumor including administering to a patient or an animal in need thereof a pharmaceutical composition, a health product, or a food additive, including 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene.

Abstract: Disclosed is use of an asparagus powder in medicines, food, and health foods for treatment of anxiety and depressive mental disorders, with active ingredients in the asparagus powder including: 15.0% or more of an asparagus saponin, 8% or more of a polysaccharide, 3.0% or more of a polyphenol, and 2.0% or more of a flavone.